U.S., Dec. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07295821) titled 'Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study' on Nov. 24.
Brief Summary: The purpose of this study is to measure efficacy and safety of osimertinib as induction therapy prior to curative intent RT and maintenance osimertinib in chemotherapy ineligible or refusal adult patients with Stage III, unresectable NSCLC with common EGFR mutations (exon 19 deletion or L858R).
Study Start Date: March 09, 2026
Study Type: INTERVENTIONAL
Condition:
Lung Cancer
Intervention:
DRUG: Osimertinib
80 mg Osimertinib QD
Recruitment Status: NOT_YET_RECRUITING
Sponsor: AstraZeneca...